MAMitsugu Araki

Mitsugu Araki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mitsugu Araki has a total of 194 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Elucidating Ligand Charge Effects in MR1 Cell-Surface Translocation Using Molecular Simulations

    by Toshiki Fujii, Mitsugu Araki, Shigeyuki Matsumoto, Biao Ma, Takao Otsuka, Gert-Jan Bekker, Narutoshi Kamiya, Hiroaki Ohno, Shinsuke Inuki, Yasushi Okuno

    The major histocompatibility complex class I-related protein 1 (MR1) is an antigen-presenting protein that binds its ligand in the endoplasmic reticulum and presents the resulting complex on the cell surface to regulate mucosal-associated invariant T (MAIT) cell function. The MAIT cells play an important role in infection defense and tissue repair and are involved in various pathological conditions. Therefore, MR1 and its ligands, which act as MAIT cell activation triggers, have garnered increasing attention. Notably, MR1 levels on the cell surface vary greatly depending on its ligands. However, the ligand recognition mechanism of MR1, as well as the structure-activity relationship of its ligands, remains poorly understood. In this study, we conducted computational analyses on the interactions between MR1 and its ligands and determined the stability of the MR1-ligand complex structures to clarify the chemical properties of ligands involved in the regulation of MR1 levels on the cell surface. Our findings provide evidence that covalent and noncovalent ligands bind to MR1 in an anionic state rather than in a previously assumed neutral state, thereby stabilizing the resulting MR1-ligand complex. Furthermore, neutralization of the positive charge derived from Arg9 upon binding of anionic ligands was identified as a key factor that contributes to the enhancement of its levels on the cell surface. Our results lay a strong foundation for further studies delving into the molecular mechanisms of ligand recognition and cell-surface localization of MR1 and will facilitate the design of ligands that activate MAIT cells.

  • Open Access

    Functional and structural analysis of KK-LC-1-specific T cell receptors from patients with lung Cancer for immunotherapy

    by Yasunori Fukushima, Yizheng Wang, Yuki Yada-Makino, Hiroyasu Komuro, Ayako Demachi-Okamura, Yusuke Sugita, Takanari Okamoto, Hiromasa Ishihara, Ryo Mizuta, Yujia Sun, et al.

  • Open Access

    Molecular recognition of natural compounds by MR1 and their implication in MAIT cell activation elucidated through McMD-based dynamic docking simulations

    by Gert-Jan Bekker, Mitsugu Araki, Kanji Oshima, Yasushi Okuno, Narutoshi Kamiya

    Major histocompatibility complex class I-related protein 1 (MR1), presents bacteria-derived ligands to T cell receptors (TCRs) as antigens as a defense against bacterial infections through activation of mucosal-associated invariant T cells (MAIT cells). Since mammals do not produce riboflavin (RBF, vitamin B2) themselves, unlike bacteria, MR1 can present the intermediates of RBF synthesis as a marker of non-self to initiate an immune response. Here, we have performed multicanonical molecular dynamics-based dynamic docking simulations to analyze the binding mechanism of RBF and two of its derivatives, photolumazine I (PLI) and III (PLIII) with MR1. We found that PLI and PLIII bind with high specificity in a manner similar to a known high-affinity ligand, RL-6-Me-7-OH. In contrast, RBF binds in multiple less specific, non-productive configurations. Subsequent structural analyses revealed that PLI and PLIII support productive TCR engagement and MAIT cell activation, while RBF fails to activate MAIT cells. Consequently, an immune response is triggered against PLI and PLIII, but not against RBF. These findings uncover the distinct binding mechanisms between the three compounds and MR1 and highlight their differential effects on MAIT cell activation in the context of bacterial infection.


  • Open Access

    Mutation of CMTR2 in Lung Adenocarcinoma Alters RNA Alternative Splicing and Reveals Therapeutic Vulnerabilities

    by Shigenari Nukaga, Kouya Shiraishi, Kenta Hamabe, Akifumi Mochizuki, Yu Hamaguchi, Emi Ogawa, Nguyen Thai Le, Yoko Shimada, Hanako Ono, Hitomi Nishinakamura, et al.

    RNA splicing dysregulation has emerged as a hallmark of cancer and a promising therapeutic target; however, its full landscape in human solid cancer remains poorly characterized. To address this, we perform alternative splicing analyses using RNA-sequencing data from 751 lung adenocarcinoma samples from our cohort integrated with 519 samples from The Cancer Genome Atlas. Visualization of splicing patterns using t-distributed stochastic neighbor embedding reveals substantial inter-tumor heterogeneity driven by distinct molecular subtypes and histological differentiation. We identify a unique molecular subtype associated with inactivating mutations in CMTR2 , which encodes Cap-specific mRNA (nucleoside-2’-O-)-methyltransferase 2. CMTR2 mutations are observed in 3.8% of cases and are predominantly truncating mutations, which form an isolated cluster within the splicing landscape. Intrinsic and CRISPR-Cas9-engineered CMTR2 mutations disrupt alternative splicing and sensitize cancer cells to sulfonamide-based RNA splicing modulators and immune checkpoint blockade therapy. Retrospective patient data confirm the increased sensitivity of CMTR2 -deficient tumors to immune checkpoint blockade therapy. These findings uncover a previously unrecognized RNA splicing deficiency in human cancers and define a molecular subtype of lung adenocarcinoma driven by RNA splicing dysregulation, suggesting targets for therapeutic intervention in lung cancer.


  • Molecular Dynamics Unveils Multiple-Site Binding of Inhibitors with Reduced Activity on the Surface of Dihydrofolate Reductase

    by Mitsugu Araki, Toru Ekimoto, Kazuhiro Takemura, Shigeyuki Matsumoto, Yunoshin Tamura, Hironori Kokubo, Gert-Jan Bekker, Tsutomu Yamane, Yuta Isaka, Yukari Sagae, et al.

    The sensitivity to protein inhibitors is altered by modifications or protein mutations, as represented by drug resistance. The mode of stable drug binding to the protein pocket has been experimentally clarified. However, the nature of the binding of inhibitors with reduced sensitivity remains unclear at the atomic level. In this study, we analyzed the thermodynamics and kinetics of inhibitor binding to the surface of wild-type and mutant dihydrofolate reductase (DHFR) using molecular dynamics simulations combined with Markov state modeling. A strong inhibitor of methotrexate (MTX) showed a preference for the active site of wild-type DHFR with minimal binding to unrelated (secondary) sites. Deletion of a side-chain fragment in MTX largely destabilized the active site-bound state, with clear evidence of binding to secondary sites. Similarly, the F31V mutation in DHFR diminished the specificity of MTX binding to the active site. These results reveal the presence of multiple-bound states whose stabilities are comparable to or higher than those of the unbound state, suggesting that a reduction in the binding affinity for the active site significantly elevates the fractions of these states. This study presents a theoretical model that more accurately interprets the altered drug sensitivity than the traditional two-state model.


  • Binding Mechanism between Platelet Glycoprotein and Cyclic Peptide Elucidated by McMD-Based Dynamic Docking

    by Gert-Jan Bekker, Kanji Oshima, Mitsugu Araki, Yasushi Okuno, Narutoshi Kamiya

    The cyclic peptide OS1 (amino acid sequence: CTERMALHNLC), which has a disulfide bond between both termini cysteine residues, inhibits complex formation between the platelet glycoprotein Ib alpha (GPIb alpha) and the von Willebrand factor (vWF) by forming a complex with GPIb alpha. To study the binding mechanism between GPIb alpha and OS1 and, therefore, the inhibition mechanism of the protein-protein GPIb alpha-vWF complex, we have applied our multicanonical molecular dynamics (McMD)-based dynamic docking protocol starting from the unbound state of the peptide. Our simulations have reproduced the experimental complex structure, although the top-ranking structure was an intermediary one, where the peptide was bound in the same location as in the experimental structure; however, the beta-switch of GPIb alpha attained a different conformation. Our analysis showed that subsequent refolding of the beta-switch results in a more stable binding configuration, although the transition to the native configuration appears to take some time, during which OS1 could dissociate. Our results show that conformational changes in the beta-switch are crucial for successful binding of OS1. Furthermore, we identified several allosteric binding sites of GPIb alpha that might also interfere with vWF binding, and optimization of the peptide to target these allosteric sites might lead to a more effective inhibitor, as these are not dependent on the beta-switch conformation.


  • Open Access

    LTK mutations responsible for resistance to lorlatinib in non-small cell lung cancer harboring CLIP1-LTK fusion

    by Shunta Mori, Hiroki Izumi, Mitsugu Araki, Jie Liu, Yu Tanaka, Yosuke Kagawa, Yukari Sagae, Biao Ma, Yuta Isaka, Yoko Sasakura, et al.

    The CLIP1-LTK fusion was recently discovered as a novel oncogenic driver in non-small cell lung cancer (NSCLC). Lorlatinib, a third-generation ALK inhibitor, exhibited a dramatic clinical response in a NSCLC patient harboring CLIP1-LTK fusion. However, it is expected that acquired resistance will inevitably develop, particularly by LTK mutations, as observed in NSCLC induced by oncogenic tyrosine kinases treated with corresponding tyrosine kinase inhibitors (TKIs). In this study, we evaluate eight LTK mutations corresponding to ALK mutations that lead to on-target resistance to lorlatinib. All LTK mutations show resistance to lorlatinib with the L650F mutation being the highest. In vitro and in vivo analyses demonstrate that gilteritinib can overcome the L650F-mediated resistance to lorlatinib. In silico analysis suggests that introduction of the L650F mutation may attenuate lorlatinib-LTK binding. Our study provides preclinical evaluations of potential on-target resistance mutations to lorlatinib, and a novel strategy to overcome the resistance.


  • Open Access

    Molecular dynamics unveils multiple-site binding of inhibitors with reduced activity on the surface of dihydrofolate reductase

    by Mitsugu Araki, Toru Ekimoto, Kazuhiro Takemura, Shigeyuki Matsumoto, Yunoshin Tamura, Hironori Kokubo, Gert-Jan Bekker, Tsutomu Yamane, Yuta Isaka, Yukari Sagae, et al.

    The sensitivity to protein inhibitors is altered by modifications or protein mutations, as represented by drug resistance. The mode of stable drug binding to the protein pocket has been experimentally clarified. However, the nature of the binding of inhibitors with reduced sensitivity remains unclear at the atomic level. In this study, we analyzed the thermodynamics and kinetics of inhibitor binding to the surface of wild-type and mutant dihydrofolate reductase (DHFR) using molecular dynamics simulations combined with Markov state modeling. A strong inhibitor of methotrexate (MTX) showed a preference for the active site of wild-type DHFR with minimal binding to unrelated (secondary) sites. Deletion of a side-chain fragment in MTX largely destabilized the active site-bound state, with clear evidence of binding to secondary sites. Similarly, the F31V mutation in DHFR diminished the specificity of MTX binding to the active site. These results reveal the presence of multiple-bound states whose stabilities are comparable to or higher than those of the unbound state, suggesting that a reduction in the binding affinity for the active site significantly elevates the fractions of these states. This study sheds light on the specific drug recognition by proteins and the selectivity of drug binding sites on protein surfaces. (199 words)

  • Open Access

    A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer

    by Mai Suzuki, Ken Uchibori, Tomoko Oh-Hara, Yumi Nomura, Ryusei Suzuki, Ai Takemoto, Mitsugu Araki, Shigeyuki Matsumoto, Yukari Sagae, Mutsuko Kukimoto-Niino, et al.

    Brigatinib-based therapy was effective against osimertinib-resistant EGFR C797S mutants and is undergoing clinical studies. However, tumor relapse suggests additional resistance mutations might emerge. Here, we first demonstrated the binding mode of brigatinib to the EGFR-T790M/C797S mutant by crystal structure analysis and predicted brigatinib-resistant mutations through a cell-based assay including N-ethyl-N-nitrosourea (ENU) mutagenesis. We found that clinically reported L718 and G796 compound mutations appeared, consistent with their proximity to the binding site of brigatinib, and brigatinib-resistant quadruple mutants such as EGFR-activating mutation/T790M/C797S/L718M were resistant to all the clinically available EGFR-TKIs. BI-4020, a fourth-generation EGFR inhibitor with a macrocyclic structure, overcomes the quadruple and major EGFR-activating mutants but not the minor mutants, such as L747P or S768I. Molecular dynamics simulation revealed the binding mode and affinity between BI-4020 and EGFR mutants. This study identified potential therapeutic strategies using the new-generation macrocyclic EGFR inhibitor to overcome the emerging ultimate resistance mutants.


  • Establishment of an MR1 Presentation Reporter Screening System and Identification of Phenylpropanoid Derivatives as MR1 Ligands

    by Takuro Matsuoka, Akira Hattori, Shinya Oishi, Mitsugu Araki, Biao Ma, Toshiki Fujii, Norihito Arichi, Yasushi Okuno, Hideaki Kakeya, Sho Yamasaki, et al.

    Mucosal-associated invariant T (MAIT) cells are innate-like T cells that are modulated by ligands presented on MHC class I-related proteins (MR1). These cells have attracted attention as potential drug targets because of their involvement in the initial response to infection and various disorders. Herein, we have established the MR1 presentation reporter assay system employing split-luciferase, which enables the efficient exploration of MR1 ligands. Using our screening system, we identified phenylpropanoid derivatives as MR1 ligands, including coniferyl aldehyde, which have an ability to inhibit the MR1-MAIT cell axis. Further, the structure-activity relationship study of coniferyl aldehyde analogs revealed the key structural features of ligands required for MR1 recognition. These results will contribute to identifying a broad range of endogenous and exogenous MR1 ligands and to developing novel MAIT cell modulators.